Across TCGA pan-cancer cohorts, RNA5SP508 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RNA5SP508’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RNA5SP508 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNA5SP508 is over-expressed in tumor.
LIHC are the cancer types where RNA5SP508 tumor–normal differential expression is most reproducible.